Page 4 - Harmony Biosciences Daily News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Harmony biosciences daily. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Harmony Biosciences Daily Today - Breaking & Trending Today

Harmony Biosciences (NASDAQ:HRMY) Receives "Buy" Rating from Needham & Company LLC

Needham & Company LLC reaffirmed their buy rating on shares of Harmony Biosciences (NASDAQ:HRMY – Free Report) in a research note published on Tuesday, Benzinga reports. They currently have a $50.00 price target on the stock. Several other research analysts also recently weighed in on HRMY. Bank of America restated an underperform rating and issued […] ....

United States , Jeffrey Dierks , Charles Schwab Investment Management Inc , Cantor Fitzgerald , Needham Company , Jupiter Asset Management Ltd , Janney Montgomery Scott , Goldman Sachs Group , Harmony Biosciences Holdings Inc , Harmony Biosciences , Free Report , Moderate Buy , Get Free Report , Schwab Investment Management , Capital Partners , Forest Capital Management , Montgomery Scott , Jupiter Asset Management , Biosciences Holdings , Harmony Biosciences Daily ,

Harmony Biosciences (NASDAQ:HRMY) Sees Large Volume Increase

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY – Get Free Report) shares saw strong trading volume on Monday . 362,007 shares traded hands during trading, a decline of 1% from the previous session’s volume of 363,865 shares.The stock last traded at $29.98 and had previously closed at $30.65. Wall Street Analysts Forecast Growth A number of equities […] ....

United States , Jeffrey Dierks , Acadian Asset Management , Jpmorgan Chase Co , Cantor Fitzgerald , Citigroup Inc , Harmony Biosciences Holdings Inc , Goldman Sachs Group , Metlife Investment Management , York Mellon Corp , Needham Company , Securities Exchange Commission , Harmony Biosciences Holdings , Get Free Report , Harmony Biosciences , Exchange Commission , New York Mellon Corp , Asset Management , Life Investment Management , Biosciences Holdings , Harmony Biosciences Daily , Nasdaq Hrmy ,

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Receives $41.00 Average Target Price from Brokerages

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Receives $41.00 Average Target Price from Brokerages
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

United States , Jeffrey Dierks , Manufacturers Life Insurance Company , Exchange Traded Concepts , Quadrant Capital Group , Cantor Fitzgerald , Needham Company , Goldman Sachs Group , Pricet Rowe Associates Inc , Harmony Biosciences Company Profile , Harmony Biosciences Holdings Inc , Ensign Peak Advisors Inc , Harmony Biosciences Holdings , Get Free Report , Harmony Biosciences , Peak Advisors Inc , Traded Concepts , Capital Group , Pricet Rowe Associates , Get Free , Biosciences Holdings , Harmony Biosciences Daily ,

Mizuho Lowers Harmony Biosciences (NASDAQ:HRMY) Price Target to $40.00

Harmony Biosciences (NASDAQ:HRMY – Get Free Report) had its price target dropped by investment analysts at Mizuho from $42.00 to $40.00 in a note issued to investors on Tuesday, Benzinga reports. The brokerage presently has a “buy” rating on the stock. Mizuho’s target price suggests a potential upside of 20.26% from the company’s previous close. […] ....

United States , Raymond James , Goldman Sachs Group , Barclays Plc , Harmony Biosciences Holdings Inc , Cantor Fitzgerald , Voloridge Investment Management , Pricet Rowe Associates Inc , Needham Company , Harmony Biosciences , Get Free Report , Biosciences Stock Down , Investment Management , Biosciences Holdings , Harmony Biosciences Daily , Nasdaq Hrmy , Lower Price Target ,

Harmony Biosciences (NASDAQ:HRMY) Given "Overweight" Rating at Cantor Fitzgerald

Cantor Fitzgerald reaffirmed their overweight rating on shares of Harmony Biosciences (NASDAQ:HRMY – Free Report) in a report published on Friday morning, Benzinga reports. The brokerage currently has a $49.00 price objective on the stock. Other equities research analysts have also recently issued reports about the stock. The Goldman Sachs Group increased their price objective […] ....

United States , Raymond James , Citigroup Inc , Harmony Biosciences Holdings Inc , Goldman Sachs Group , Needham Company , Cantor Fitzgerald , Metlife Investment Management , Acadian Asset Management , York Mellon Corp , Jpmorgan Chase Co , Harmony Biosciences , Free Report , Moderate Buy , Biosciences Stock Down , Get Free Report , New York Mellon Corp , Asset Management , Life Investment Management , Biosciences Holdings , Harmony Biosciences Daily , Nasdaq Hrmy , Reiterated Rating ,